Can Bio-Thera’s BAT8013 turn regulatory T-cell depletion into a workable solid-tumor strategy?
Bio-Thera has dosed the first patient in BAT8013’s Phase 1 trial. See why safety, Treg selectivity and dose choice will decide its future.
Pharma & Biotech